Impact of allogeneic blood transfusions on clinical outcomes in severely burned patients by Kaserer, Alexander et al.








Impact of allogeneic blood transfusions on clinical outcomes in severely
burned patients
Kaserer, Alexander ; Rössler, Julian ; Slankamenac, Ksenija ; Arvanitakis, Michael ; Spahn, Donat R ;
Giovanoli, Pietro ; Steiger, Peter ; Plock, Jan A
Abstract: BACKGROUND: Allogeneic blood transfusions are common in the treatment of severely
burned patients as surgery may lead to major blood loss. However, transfusions are associated with
a number of adverse events. Therefore, the purpose of our study was to investigate the impact of allo-
geneic blood transfusions on clinical outcomes in severely burned patients. METHODS: This retrospective
study included all adult patients admitted to the burn center of the University Hospital Zurich between
January 2004 and December 2014, with burn injuries greater than 10% of total body surface area and
receiving both surgical and intensive care treatment. Primary Endpoints were infectious or thromboem-
bolic complications and mortality and secondary endpoints were length of hospital and ICU stay. Simple
and multivariable logistic and linear regression models, adjusted for injury severity and confounders, were
applied. RESULTS: 413 patients met inclusion criteria of which 212 patients (51%) received allogenic
blood products. After adjustment for injury severity and confounders, red blood cell transfusion was
independently associated with wound infection (OR 13.5, 95% CI 1.7-107, p = 0.014), sepsis (OR 8.3,
4.2-16.3; p < 0.001), pneumonia (OR 4.7, 2.2-10.0; p < 0.001), thrombosis (OR 3.0, 1.2-7.4; p = 0.015),
central line infection (OR 34.7, 4.6-260; p = 0.001) and a longer ICU and hospital stay (difference 17.7,
CI 12.1-23.4, p < 0.001 and 22.0, 15.8-28.2, p < 0.001, respectively). Fresh frozen plasma transfusion
was independently associated with a longer ICU and hospital stay (difference 13.7, 95% CI 5.5-21.8, p =
0.001 and 13.5, 4.6-22.5, p = 0.003, respectively). Platelet transfusion was independently associated with
systemic inflammatory response syndrome (OR 4.5, 1.3-15.5; p = 0.018) and mortality (OR 5.8, 2.1-16.0;
p = 0.001). CONCLUSION: Transfusion of allogeneic blood products is associated with an increased
infection rate and thromboembolic morbidity and a longer hospital stay in severely burned patients.
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Background: Allogeneic blood transfusions are common in the treatment of severely burned 25 
patients as surgery may lead to major blood loss. However, transfusions are associated with a 26 
number of adverse events. Therefore, the purpose of our study was to investigate the impact of 27 
allogeneic blood transfusions on clinical outcomes in severely burned patients. 28 
 29 
Methods: This retrospective study included all adult patients admitted to the burn center of the 30 
University Hospital Zurich between January 2004 and December 2014, with burn injuries 31 
greater than 10% of total body surface area and requiring both surgical and intensive care 32 
treatment. Primary Endpoints were infectious or thromboembolic complications and mortality 33 
and secondary endpoints were length of hospital and ICU stay. Simple and multivariable 34 
logistic and linear regression models, adjusted for injury severity and confounders, were 35 
applied. 36 
 37 
Results: 413 patients met inclusion criteria of which 212 patients (51%) required allogenic 38 
blood products. After adjustment for injury severity and confounders, red blood cell transfusion 39 
was independently associated with wound infection (OR 13.5, 95% CI 1.7 to 107, p=0.014), 40 
sepsis (OR 8.3, 4.2 to 16.3; p<0.001), pneumonia (OR 4.7, 2.2 to 10.0; p<0.001), thrombosis 41 
(OR 3.0, 1.2 to 7.4; p=0.015), central line infection (OR 34.7, 4.6 to 260; p=0.001) and a longer 42 
ICU and hospital stay (difference 17.7, 95% CI 12.1 to 23.4, p<0.001 and 22.0, 15.8 to 28.2, 43 
p<0.001, respectively). Fresh frozen plasma transfusion was independently associated with a 44 
longer ICU and hospital stay (difference 13.7, 95% CI 5.5 to 21.8, p=0.001 and 13.5, 4.6 to 45 
22.5, p=0.003, respectively). Platelet transfusion was independently associated with systemic 46 
inflammatory response syndrome (OR 4.5, 1.3 to 15.5; p=0.018) and mortality (OR 5.8, 2.1 to 47 




Conclusion: Transfusion of allogeneic blood products is associated with an increased infection 50 
rate and thromboembolic morbidity and a longer hospital stay in severely burned patients.  51 
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Transfusion and coagulation management in severely burned patients is challenging. Thermal 57 
injuries with extended soft tissue injury and subsequent inflammatory response lead to diffuse 58 
activation of coagulation factors culminating in a hypercoagulable state.[1, 2] While this alone 59 
increases the risk of developing venous thromboembolism, patients suffering from burn injuries 60 
are further exposed to numerous additional risk factors for infections, like repetitive surgical 61 
procedures, use of intravascular catheters, prolonged immobilization and multiple blood 62 
transfusions.[3, 4] Transfusions are common in burn surgery, as tangential excision may lead 63 
to major blood loss.[5] Here, apart from balanced volume replacement, hemostatic resuscitation 64 
traditionally meant early transfusion of packed red blood cells (RBC), fresh frozen plasma 65 
(FFP) and platelet concentrate (PLT) at a fixed ratio.[6, 7] However, allogenic blood 66 
transfusions are associated with a number of adverse events and it was shown that their 67 
reduction improves clinical outcomes including mortality.[4, 8] A factor-based coagulation 68 
management guided by viscoelastic point of care tests[9] has recently been proposed as a new 69 
approach of hemostatic resuscitation leading to a decreased transfusion requirement with 70 
beneficial outcomes in trauma patients.[10-13] However, burn victims are not taken specifically 71 
into account. Identification of adverse effects of allogeneic blood transfusions in severely 72 
burned patients may further promote the implementation of such goal directed coagulation 73 
management in burn patients in order to reduce transfusion requirements.[14] Therefore, the 74 
purpose of our retrospective study was to investigate the impact of allogeneic blood transfusions 75 
on clinical outcomes in severely burned patients. 76 
 77 
Methods 78 
Study setting and patient selection 79 
This study was approved by the responsible ethics committee of the canton of Zurich (KEK-80 
ZH-Nr.: 2015-111). Data handling was in accordance with the Good Clinical Practice 81 
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Guidelines and the Declaration of Helsinki for biomedical research. The study included all adult 82 
patients admitted to the burn center of the University Hospital Zurich between January 2004 83 
and December 2014 with burn injuries greater than 10% of total body surface area (TBSA) and 84 
requiring both surgical and intensive care treatment. No substantial changes to the transfusion 85 
and coagulation algorithm were made during the observed period. To prevent a possible bias of 86 
our results we purposely terminated the observation period at the end of 2014 as in 2015 a new 87 
transfusion and coagulation algorithm was introduced at our burn center. Exclusion criteria 88 
were incomplete medical records, conservatively treated superficial burns (grade I-IIa), 89 
secondary admissions with older injuries (after the acute phase treatment in regional hospital 90 
or abroad) and all patients who received palliation-focused care because of terminal injuries. 91 
Figure 1 presents a flowchart of the patient selection. 92 
 93 
Data collection 94 
From the internal electronic database of the University Hospital Zurich, we extracted patient’s 95 
demographics, abbreviated burn severity index (ABSI) score[15], TBSA, co-morbidities, 96 
additional injuries including inhalation injury, administered RBC, PLT and FFP transfusions, 97 
thromboembolic events, systemic inflammatory response syndrome (SIRS), sepsis, pneumonia, 98 
central line infections, urinary tract infections, wound infections, length of ICU and hospital 99 
stay as well as mortality. Additionally, we reviewed anesthesia records for administered blood 100 
products and clotting factors during all surgical procedures. Extracted data was entered into a 101 
spreadsheet (Excel, Microsoft Office 2016, Redmond, WA, United States) and scores and 102 
values were calculated. Comorbidities were summarized calculating the Charlson co-morbidity 103 
index.[16] All patients received venous thromboembolism prophylaxis with low molecular 104 
weight heparin. SIRS and sepsis were defined according to the definition consensus of the 105 
American Burn Association related to the observation period.[17] The ABSI is a model to 106 
assess accurately[15] probability of mortality, that uses age, TBSA, inhalational injury, gender 107 
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and the presence of full thickness burns to generate a score. It is therefore also used as an 108 
equivalent of burn injury severity. 109 
 110 
Endpoints and outcome variables 111 
The aim of our study was to analyze the impact of allogeneic blood transfusions on clinical 112 
outcomes. Primary endpoints were thromboembolic events, SIRS, sepsis, pneumonia, central 113 
line infection, urinary tract infection, wound infections and mortality. Secondary endpoints 114 
were length of ICU and hospital stay in severely burned patients. 115 
 116 
Statistical analyses 117 
In a first step of the analysis, we expressed distribution of variables using means and standard 118 
deviation (SD) for normally distributed continuous data, and medians and interquartile ranges 119 
(IQR) for non-normally distributed data. We tested data for normality with the Kolmogorow-120 
Smirnow test and performed quantile-quantile plots of dependent variables. In a second step, 121 
we used simple logistic and linear regression models, followed by the main analysis, a 122 
multivariable logistic and linear regression model for the following parameters: thrombosis, 123 
SIRS, sepsis, pneumonia, central line-associated infections, urinary tract infections, wound 124 
infection, mortality, length of ICU stay and length of hospital stay. Thereby we adjusted for the 125 
following confounders known from the literature, based on the clinical experience and 126 
statistical models: ABSI-score, Charlson co-morbidity index, the presence of additional injuries 127 
and the administration of clotting factors.  128 
For all results, we reported point estimates, 95% confidence intervals (CI) and p-values ≤ 0.05 129 
considered significant. We performed the statistical analyses using the statistical program 130 






We retrospectively screened 810 patients admitted to the burn ICU of the University Hospital 135 
of Zurich during a 10-year period from 2004 to 2104. We then excluded 397 patients who did 136 
not meet inclusion criteria. Of the remaining 413 patients, 212 patients (51%) required allogenic 137 
blood products, while the other 201 patients (49%) did not (Figure 1). 138 
The two groups were well balanced in size with a similar mean age. The prevalence of 139 
comorbidities was comparable with a Charlson co-morbidity index < 4 in 91.5% of patients 140 
who required transfusions and in 94.0% of patients who did not. Patients requiring allogenic 141 
blood transfusions were female in 32.5% compared to 18.9% in non-transfused patients. Further 142 
group differences were found regarding the severity of the burn injury, where patients receiving 143 
allogenic blood products had a larger burned TBSA and a higher ABSI score (6±2 vs. 8±2), as 144 
well as more inhalation or other additional injuries (Table 1). These group differences were 145 
considered as confounders in our regression model. 146 
Among patients requiring RBC transfusions, sepsis occurred in nearly half of all patients. Other 147 
frequently observed complications were pneumonia (25%), central line infections (17%) and 148 
thrombosis (12.7%). Table 2 gives a detailed overview on the incidence of observed 149 
complications. After adjusting for confounders, RBC transfusion was independently associated 150 
with central line infections, wound infections, sepsis, pneumonia and thrombosis. Moreover, 151 
RBC transfusion was independently associated with a longer ICU and hospital stay. Unadjusted 152 
and adjusted odds ratios for each outcome are presented in Table 2. Mortality was not affected 153 
by RBC transfusions after adjustment (Table 2, Figure 2). 154 
FFP was administered in 51 out of 413 included patients (12%). Leading complications in 155 
patients requiring FFP transfusions were sepsis (60.8%), pneumonia (33.3%) and central line 156 
infections (23.5%). Incidence of all observed complications as well as unadjusted and adjusted 157 
odds ratio for each outcome is presented in Table 3 and Figure 2. After adjustment, FFP 158 
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transfusion was independently associated with a longer ICU and hospital stay only. No 159 
significant association with other outcomes, in particular mortality, was observed (Table 3). 160 
PLT transfusions were administered in 31 patients out of 413 included patients (7.5%). 161 
Frequently observed complications in patients requiring PLT transfusion were sepsis (74.2%), 162 
pneumonia (41.9%), thrombosis (22.6%) and central line infections (22.6%). Mortality was 163 
high in patients requiring PLT transfusion (58.1%). Table 4 presents unadjusted and adjusted 164 
odds ratios in detail. After adjustment, PLT transfusion was independently associated with 165 
SIRS and mortality, but not with sepsis or other outcomes (Table 4, Figure 2). 166 
 167 
Discussion 168 
Allogeneic blood transfusions are common in the treatment of severely burned patients as 169 
surgery may lead to major blood loss.[5, 18, 19] Currently, fixed ratio transfusion of RBC, PLT 170 
and FFP is still widely used and recommended for hemostatic resuscitation.[6, 7] However, 171 
transfusions may additionally lead to complications and worse clinical outcomes.[4, 8] In this 172 
study, we retrospectively analyzed the data of 413 burn patients admitted to the largest burn 173 
center in Switzerland. We calculated multiple regression models adjusting for possible 174 
confounders and found that RBC transfusion was associated with central line infections, wound 175 
infections, sepsis, pneumonia, thrombosis and a longer ICU and hospital stay; FFP transfusion 176 
was associated with a longer ICU and hospital stay and PLT transfusion was independently 177 
associated with SIRS and mortality. 178 
Allogeneic blood transfusion is associated to several adverse effects.[4, 8] Repetitive surgeries 179 
with major blood loss and a concomitant hypercoagulability of burn patients complicates 180 
hemostatic and transfusion management.[1, 2, 7]  As a result of the overwhelming response to 181 
severe thermal injury burn patients have increased levels of proinflammatory cytokines, which 182 
blunt erythropoietic response in the bone marrow.[20] The distinction between acute blood loss 183 
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anemia and anemia due to bone marrow dysfunction in burn patients is therefore an essential 184 
framework to lower the incidence of anemia and reduce transfusion requirement. For non-185 
burned patients a multimodal treatment concept was introduced to reduce allogeneic blood 186 
transfusions. Such Patient Blood Management programs were confirmed to improve outcomes 187 
and reduce costs.[8, 21, 22] However, burn patients are not specially taken into account by such 188 
programs and physicians are still treating severely burned patients with an ample of transfusions 189 
reaching an overall transfusion rate up to 97.7%.[7, 18] The adverse effect of such an 190 
overflowing transfusion management cannot be neglected. Palmieri et al. showed that a 191 
restrictive transfusion strategy is feasible and well tolerated in burned patients.[23] Moreover, 192 
her group showed that a restrictive transfusion strategy halved the administered blood products 193 
without worsening outcomes in major burns.[24] In another prospective randomized trial of 345 194 
patients Palmieri et al. demonstrated, that a restrictive transfusion strategy is not only well 195 
tolerated, but also beneficial by reducing length of ventilatory support and ICU stay.[25] While 196 
these trials were conducted in multiple centers in the United States, this conclusion is in line 197 
with our findings showing an increased ICU and hospital stay in patients requiring blood 198 
transfusions in a single European center. This implies a generalizability of the underlying results 199 
regarding the impact of transfusions on clinical outcomes. 200 
Preventing infections is important in the treatment of burn patients. The burned body area is 201 
missing its natural barrier function and patients treated with allogeneic blood products are 202 
further exposed to a transfusion-related immunomodulation effect, as well as changes that may 203 
occur with old blood.[26] Moreover, a restrictive management in the antibiotic therapy should 204 
prevent the development of multi-resistant germs. These factors favor the occurrence of 205 
infections in burn patients, which eventually may lead to sepsis. Our findings reflect this fact 206 
by showing an independent association of RBC transfusion with central line infections, wound 207 
infections, pneumonia and sepsis confirming the findings of Palmieri et al.[27]  208 
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In line with our results, transfusion was detected as a possible risk factor for thrombosis in 209 
burned patients.[3, 28] Recently, an association of perioperative RBC transfusion with venous 210 
thromboembolism was confirmed in 750.937 non-burned patients undergoing surgery.[29] 211 
Burned patients additionally suffer from extended soft tissue injury and subsequent 212 
inflammatory response leading to a diffuse activation of coagulation factors, which culminates 213 
in a hypercoagulable state.[1, 2] While this alone increases the risk of developing venous 214 
thromboembolism, burn patients are further exposed to numerous additional risk factors, like 215 
the need of central lines or other intravascular catheters and prolonged immobilization. 216 
Glance et al. showed an association of intraoperative blood transfusion with a higher risk of 217 
mortality in anemic patients undergoing noncardiac surgery.[4] But also in burn patients 218 
Palmieri et al. and Tavousi et al. found an increased mortality due to blood transfusions.[27, 219 
30] However, in our analysis only PLT transfusion was independently associated with 220 
mortality, but not RBC or FFP transfusion. PLT transfusion is not frequently necessary in 221 
burned patients. Platelets drop below a critical threshold predominantly in acute situations such 222 
as major bleeding requiring successive massive transfusion. Therefore, we interpret the 223 
association of PLT transfusion with mortality more as an expression of a deranging situation, 224 
rather than a causation. 225 
 226 
Limitations 227 
This study has some limitations. Importantly it was a retrospective study and we are limited by 228 
the present methodological confines, as a retrospective analysis can only indicate a possible 229 
association and not causation. Further, as for all post-hoc studies, a power analysis would be 230 
inappropriate, however the confidence intervals of certain events in the regression model 231 
suggest an inadequate sample size. Due to overlapping transfusion requirements for different 232 
blood products, none of our patients had FFP or PLT transfusion only. This might mask the 233 
isolated effect of each blood product partly. Blood products are known to be transfused in higher 234 
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amounts in sicker patients. Thereby, any retrospective analysis about blood and outcome is 235 
challenging. Although patients requiring blood transfusions had a larger TBSA and more 236 
concomitant inhalation injuries, we are confident that our approach is sufficient to capture 237 
possible negative impact of allogenic blood products. We adjusted our analysis for the ABSI 238 
score, which was recently proven for its accuracy.[15] Additionally, with the adjustment for the 239 
Charlson co-morbidity index, the presence of additional injuries and the administration of 240 
clotting factors we eliminated other possible confounders in order to focus on the impact of 241 
transfusions on our outcomes. However, there might be some confounders for which we cannot 242 
account and correct retrospectively. Additional confounding factors known for blood products 243 
(e.g., elderly, cardiovascular comorbidities, anemia) can reasonably be excluded as this 244 
analyzed group of patients is in general a young and healthy population without comorbidities 245 
(mean age of 43-45 years). Therefore, we are convinced that our data are robust and conclusive. 246 
 247 
Conclusion 248 
Transfusion of allogeneic blood products is associated with an increased morbidity in severely 249 
burned patients. Our findings therefore support the approach of a restrictive transfusion strategy 250 
in severely burned patients. 251 
  252 
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Table 1: Patients’ characteristic. 375 
 
Patients requiring NO 
allogeneic blood transfusions 
(n=201) 
Patients requiring allogeneic 
blood transfusions 
(n=212) 
Age, years, mean (SD) 43.8 (16.3) 45.8 (17.9) 
Sex female (%) 38 (18.9%) 69 (32.5%) 












Burn % TBSA, median (IQR) 15 (12 – 24) 30 (18 – 41) 
ABSI score, mean (SD) 6 (2) 8 (2) 
3rd Burn 88 (43.8%) 163 (76.9%) 
Inhalation injury 21 (10.4%) 36 (17.0%) 
Additional injuries 
(other than inhalation injury) 
3 (1.5%) 12 (5.7%) 












unadjusted OR (95% CI) p-value adjusted OR (95% CI) p-value 
Thrombosis 8 (4.0%) 27 (12.7%) 3.5 (1.6 to 7.9) p=0.002 3.0 (1.2 to 7.4) p=0.015 
SIRS 4 (2.0%) 15 (7.1%) 3.8 (1.2 to 11.5) p=0.021 2.1 (0.6 to 7.5) p=0.245 
Sepsis 13 (6.5%) 103 (48.6%) 13.7 (7.3 to 25.5) p<0.001 8.3 (4.2 to 16.3) p<0.001 
Pneumonia 10 (5.0%) 53 (25%) 6.4 (3.1 to 12.9) p<0.001 4.7 (2.2 to 10.0) p<0.001 
Central line-associated infections 1 (0.5%) 36 (17.0%) 40.9 (5.6 to 301) p<0.001 34.7 (4.6 to 260) p=0.001 
Urinary tract infections 4 (2.0%) 14 (6.6%) 3.5 (1.1 to 10.8) p=0.030 2.6 (0.7 to 9.0) p=0.138 
Wound infection 1 (0.5%) 19 (9.0%) 19.7 (2.6 to 149) p=0.004 13.5 (1.7 to 107) p=0.014 
Mortality 19 (9.5%) 44 (20.8%) 2.5 (1.4 to 4.5) p=0.002 0.8 (0.4 to 1.7) p=0.504 







Length of ICU stay (days) 7 (3 – 12) 28 (13.5 – 43) 26.1 (20.9 to 31.2) p<0.001 17.7 (12.1 to 23.4) p<0.001 
Length of hospital stay (days) 15 (11 – 22) 36 (21.5 – 58) 27.9 (22.4 to 33.4) p<0.001 22.0 (15.8 to 28.2) p<0.001 
Adjusted for the following confounders: ABSI-score, Charlson co-morbidity index, the presence of additional injuries and administration of clotting factors. All 












unadjusted OR (95% CI) p-value adjusted OR (95% CI) p-value 
Thrombosis 30 (8.3%) 5 (9.8%) 1.2 (0.4 to 3.3) p=0.72 0.6 (0.2 – 1.6) p=0.303 
SIRS 14 (3.9%) 5 (9.8%) 2.7 (0.9 to 7.8) p=0.068 1.9 (0.7 – 3.9) p=0.294 
Sepsis 85 (23.5%) 31 (60.8%) 5.1 (2.7 to 9.3) p<0.001 1.6 (0.9 – 3.8) p=0.119 
Pneumonia 46 (12.7%) 17 (33.3%) 3.4 (1.8 to 6.6) p<0.001 1.5 (0.7 – 3.0) p=0.275 
Central line-associated infections 25 (6.9%) 12 (23.5%) 4.1 (1.9 to 8.9) p<0.001 1.7 (0.8 – 3.9) p=0.200 
Urinary tract infections 15 (4.1%) 3 (5.9%) 1.4 (0.4 to 5.2) p=0.57 0.8 (0.2 – 3.2) p=0.798 
Wound infection 12 (3.3%) 8 (15.7%) 5.4 (2.1 to 14.0) p<0.001 2.3 (0.8 – 6.2) p=0.114 
Mortality 48 (13.3%) 15 (29.4%) 2.7 (1.4 to 5.4) p=0.004 2.0 (0.8 – 4.9) p=0.143 




adjusted difference  
(95% CI) 
 
Length of ICU stay (days) 11 (6 – 25) 33 (15 – 44) 28.0 (19.8 to 36.3) p<0.001 13.7 (5.5 – 21.8) p=0.001 
Length of hospital stay (days) 21 (13 – 35) 39 (23 – 66) 28.7 (19.8 to 37.6) p<0.001 13.5 (4.6 – 22.5) p=0.003 
Adjusted for the following confounders: ABSI-score, Charlson co-morbidity index, the presence of additional injuries and administration of clotting factors. All 
parametric results were presented as median (interquartile range). OR = odds ratio; CI = confidence interval; SIRS = Systemic Inflammatory Response Syndrome; 
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unadjusted OR (95% CI) p-value adjusted OR (95% CI) p-value 
Thrombosis 28 (7.3%) 7 (22.6%) 2.4 (1.4 to 4.2) p=0.002 1.9 (0.7 to 5.3) p=0.212 
SIRS 13 (3.4%) 6 (19.4%) 6.8 (2.4 to 19.4) p<0.001 4.5 (1.3 to 15.5) p=0.018 
Sepsis 93 (24.3%) 23 (74.2%) 8.9 (3.8 to 20.6) p<0.001 2.2 (0.9 to 5.5) p=0.101 
Pneumonia 50 (13.1%) 13 (41.9%) 4.8 (2.2 to 10.4) p<0.001 1.9 (0.8 to 4.4) p=0.158 
Central line-associated infections 30 (7.9%) 7 (22.6%) 3.4 (1.4 to 8.6) p=0.009 1.2 (0.4 to 3.4) p=0.706 
Urinary tract infections 16 (4.2%) 2 (6.5%) 1.6 (0.3 to 7.2) p=0.56 0.9 (0.2 to 4.4) p=0.862 
Wound infection 17 (4.5%) 3 (9.7%) 2.3 (0.6 to 8.3) p=0.20 0.6 (0.2 to 2.5) p=0.489 
Mortality 45 (11.8%) 18 (58.1%) 10.4 (4.8 to 22.6) p<0.001 5.8 (2.1 to 16.0) p=0.001 
Adjusted for the following confounders: ABSI-score, Charlson co-morbidity index, the presence of additional injuries and administration of clotting factors. OR = 





Figure 1: Flowchart of patient selection. 384 
 385 
 386 
Figure 2: Odds ratios. The effect of allogeneic blood transfusion on clinical outcome in 387 
severely burned patients. Odds ratios are from the multivariate regression models adjusted for 388 
ABSI-score, Charlson co-morbidity index, presence of additional injuries and administration of 389 
clotting factors. 390 
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